Phase II escalation study of sorafenib in patients with metastatic renal cell carcinoma who have been previously treated with anti‐angiogenic treatment

Abstract

Sorafenib at doses of 400-600 mg twice a day continuously results in acceptable and well tolerated salvage treatment after VEGFR tyrosine kinase inhibitor failure. In progressive patients, treatment with a higher dose could be a valid option and B-RAF mutations may be an interesting predictive marker to be studied in a larger randomized trial.